Theralase Technologies Inc. (TLTFF)
- Previous Close
0.1296 - Open
0.1296 - Bid 0.1160 x --
- Ask 0.1378 x --
- Day's Range
0.1260 - 0.1308 - 52 Week Range
0.0800 - 0.2100 - Volume
27,000 - Avg. Volume
29,314 - Market Cap (intraday)
33.995M - Beta (5Y Monthly) 1.38
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Nov 27, 2024 - Dec 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.
www.theralase.comRecent News: TLTFF
View MorePerformance Overview: TLTFF
Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TLTFF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TLTFF
View MoreValuation Measures
Market Cap
30.32M
Enterprise Value
30.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
45.58
Price/Book (mrq)
27.00
Enterprise Value/Revenue
44.74
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-81.88%
Return on Equity (ttm)
-238.55%
Revenue (ttm)
920.62k
Net Income Avi to Common (ttm)
-4.41M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
428.36k
Total Debt/Equity (mrq)
20.58%
Levered Free Cash Flow (ttm)
-1.61M
Company Insights: TLTFF
TLTFF does not have Company Insights